Clinical Study
Effectiveness and Safety of Peritoneal Dialysis Treatment in Patients with Refractory Congestive Heart Failure due to Chronic Cardiorenal Syndrome
Table 1
Characteristics of study patients.
| | Characteristic | Group A
() | Group B
() |
| | Age (years) | 53.6 ± 15.4 | 68.3 ± 12.7 | | Men (%) | 8 (57.1) | 14 (63.6) | | Diabetes mellitus (%) | 5 (35.7) | 12 (54.5) | | Body mass index | 21.0 ± 1.98 | 22.4 ± 1.89 | | Blood urea/creatinine | 36.8 ± 10.2 | 14.7 ± 3.03 | | Cardiomyopathy | | | | Ischemic | 6 (42.9) | 17 (77.3) | | Rheumatic | 3 (21.4) | 1 (4.54) | | Idiopathic | 5 (35.7) | 2 (9.09) | | Others/unknown | - | 2 (9.09) | | Potential causes of renal damage other than heart failure | | | | Diabetic kidney disease | 1 (7.14) | 10 (45.5) | | Chronic glomerular nephritis | - | 3 (13.6) | | Hypertensive glomerular sclerosis | 8 (57.1) | 3 (13.6) | | Others/unknown | - | 6 (27.3) | | NYHA stage | | | | III | 6 (42.9) | 9 (40.9) | | IV | 8 (57.1) | 13 (59.1) | | eGFR (mL/min/1.73 m2) | 27.8 ± 9.87 | 15.1 ± 3.51 | | Hemoglobin (g/dL) | 92.0 ± 14.5 | 86.5 ± 11.4 | | Serum cholesterol (mmol/L) | 4.08 ± 1.01 | 4.84 ± 1.89 | | Serum triglyceride (mmol/L) | 2.55 ± 1.34 | 2.98 ± 1.01 | | Serum albumin (g/L) | 33.2 ± 4.12 | 32.4 ± 4.81 | | Systolic blood pressure (mmHg) | 115 ± 16 | 159 ± 24 | | Diastolic blood pressure (mmHg) | 64 ± 18 | 89 ± 19 | | Atrial fibrillation | 3 (21.4) | 8 (36.4) | | Prolonged Q-Tc interval | 6 (42.9) | 9 (40.9) | | Drug prescription after PD (%) | | | | ACEI/ARB | 9 (64.3) | 20 (90.1) | | Beta-blockers | 12 (85.7) | 21 (95.5) | | Diuretics | 11 (78.6) | 22 (100) | | Statins | 13 (92.9) | 20 (90.1) | | Aspirin | 8 (57.1) | 13 (59.1) | | Erythropoietin | 2 (14.3) | 8 (36.4) | | Insulin (% of DM) | 4 (80) | 12 (100) |
|
|
Note. Compared with group A ; . eGFR: estimated glomerular filtration rate. |
